Press Release

     View printer-friendly version
    << Back
    Blueprint Medicines to Report Fourth Quarter and Full Year 2017 Financial Results on Wednesday, February 21, 2018

    CAMBRIDGE, Mass., Feb. 14, 2018 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Wednesday, February 21, 2018 to report its fourth quarter and full year 2017 financial results and provide a corporate update.


    To access the live conference call, please dial 1-855-728-4793 (domestic) or 1-503-343-6666 (international), and refer to conference ID 3391675. A live webcast will be available under "Events and Presentations" in the Investors section of Blueprint Medicines' website at The archived webcast will be available on Blueprint Medicines' website approximately two hours after the conference call and will be available for 30 days following the call.

    About Blueprint Medicines

    Blueprint Medicines is developing a new generation of targeted and potent kinase medicines to improve the lives of patients with genomically defined diseases. Its approach is rooted in a deep understanding of the genetic blueprint of cancer and other diseases driven by the abnormal activation of kinases. Blueprint Medicines is advancing four programs in clinical development for subsets of patients with gastrointestinal stromal tumors, hepatocellular carcinoma, systemic mastocytosis, non-small cell lung cancer, medullary thyroid cancer and other advanced solid tumors, as well as multiple programs in research and preclinical development. For more information, please visit

    Cision View original content with multimedia:

    SOURCE Blueprint Medicines

    Kristin Hodous, 617-714-6674,, or Jim Baker, 617-844-8236,

    Print Page  | E-mail Page  | RSS Feeds  | E-mail Alerts  | Financial Tear Sheet